Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hims & Hers (NYSE: HIMS) is attracting investors looking to buy the dip in this impressive growth stock. Where to invest ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Hims & Hers thrives with telehealth growth, strong subscriber base, and expanding products, despite challenges like ...

The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...